13 July 2016
MSD Animal Health Prepares for the Launch of BRAVECTO® Spot-On for Cats
Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks
Milton Keynes, July 13, 2016 – MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA.) has launched BRAVECTO® (fluralaner) Spot-On Solution for cats, a Spot-On treatment for fleas and ticks effective for 12 weeks following a single dose. BRAVECTO® Spot-On Solution for cats will be available on the market in July this year, following the success of BRAVECTO® chewable tablets for dog, launched two years ago and now the preferred choice of dog POM-V ectoparasiticide for ticks in veterinary practices.1
BRAVECTO® Spot-On Solution for cats, a systemic insecticide and acaricide, is indicated for the treatment of flea and tick infestations on cats and provides immediate and persistent flea and tick killing activity for 12 weeks. It is applied topically using the new “Twist’n’Use”™ pipette design which means the cap doesn’t need to be removed, making it easy to use. Full product details are described in the summary of product characteristics (SPC).
Amanda Melvin, Senior Product Manager: “We’re very excited about this approval as it will allow us to build on the success of our BRAVECTO chewable tablets for dogs and provide veterinarians and cat owners with another tool in the fight against ticks and fleas. Being able to offer a full 12 week protection means convenience for cat owners and improved compliance rates for veterinarians, so everyone benefits.”
Vets interested in learning more about BRAVECTO Spot-On should contact their MSD Animal Health representative.
1 GFK Data Dec 2015 52.5% MS Brands used for comparison are Bravecto, Frontline combo dog, Seresto, Advantix, Nexgard, Nexgard Spectra, Vectra 3D, Activyl Tick plus, Pestigon, Frontect, Promeris duo